Visiongain has published a new report: Global Respiratory Drug Delivery Technologies Market, (COVID-19 Impact Analysis):- Market Segment by Product (Formulations and Devices), by Type (Dry Powder, Suspension Aerosol, and Solution Aerosol), by Product Type (Metered Dose Inhalers (MDIS), Dry Powder Inhalers (DPIs), Nebulizers and Accessories), by Nebulizers Type (Soft Mist Nebulizers, Jet Nebulizers and Ultrasonic Nebulizers), by Canister Type (Plain Canisters and Coated Canister), by Application (Asthma. COPD, Cystic Fibrosis and Others) and End User (Homecare, Hospitals & Clinics and Others) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (“V”-shaped, “W”-shaped, “U”-shaped, “L”-shaped) Profiles of Leading Companies, Region and Country.
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
Increasing prevalence and incidence of respiratory diseases
Prevalence and incidence of respiratory diseases are increasing worldwide because of various factors including pollution, unhealthy lifestyle, and tobacco smoking. According to the Global Burden of Diseases Study (2017), there were approximately 3.2 million deaths due to COPD (Chronic Obstructive Pulmonary Disease and 495,000 due to asthma. COPD accounts to be the seventh leading cause of life loss due to premature deaths. There has been a rise in demand and the…
